Navigation Links
Weizmann Institute scientists develop a new approach to treating autoimmune disease
Date:6/2/2008

In autoimmune diseases, the immune system turns against the body's own tissues and organs, wreaking havoc and destruction for no apparent reason. Partly because the origins of these diseases are so obscure, no effective treatment exists, and the suffering they inflict is enormous. Now Weizmann Institute scientists have developed a method that in the future may make it possible to treat autoimmune diseases effectively without necessarily knowing their exact cause. Their approach is equivalent to sending a police force to suppress a riot without seeking out the individuals who instigated the unrest.

In healthy people, a small but crucial group of immune cells called regulatory T cells, or T-regs, keeps autoimmunity in check, but in people with inflammatory bowel disease (IBD), one of the most common autoimmune disorders, too few of these cells appear in the diseased intestine, and the ones that do fail to function properly. The new Weizmann Institute approach consists of delivering highly selective, genetically engineered functioning T-regs to the intestine. The study was conducted by Dr. Eran Elinav, a physician from Tel Aviv Sourasky Medical Center's gastroenterology institute who is working toward his Ph.D. at the Weizmann Institute, and lab assistant Tova Waks, in the laboratory of Prof. Zelig Eshhar of the Immunology Department.

Relying on Eshhar's earlier work in which he equipped a different type of T cell to zero in on cancerous tumors, the team genetically engineered T-regs, outfitting these cells with a modular receptor consisting of three units. One of these units directed the cells to the intestine while the other two made sure they became duly activated. As reported in the journal Gastroenterology, the approach proved effective in laboratory mice with a disease that simulates human IBD: Most of the mice treated with the genetically-engineered T-regs developed only mild inflammation or no inflammation at all.

The cells produ
'/>"/>

Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Weizmann Institute scientists produce the first smell map
2. OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer
3. OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy
4. ECRI Institute Issues Priority Alert About Two Infusion Pumps
5. MedAssurants Dr. Keith Dunleavy to Present at AHIPs Institute 2008
6. Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period
7. Worcester Polytechnic Institute announces 2008 Chairmans Exemplary Faculty Prize winners
8. Population Health Impact Institute to Host First Methods Evaluation Process(TM) (MEP(TM)) Workshop at Annual CMSA Conference
9. Presidential Candidates Health Care Plans Lack Key Reform Elements, Aspen Institute Finds
10. Institute for Integrative Nutrition Begins Road Tour
11. OHSU Cancer Institute researchers pinpoint how smoking causes cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Are angry women more like men? 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...omen who got injections report reduced pain and s...) -- The first evidence that gene therapy can ease... has been reported by American and German research...e women,s affected joints. IL-1Ra protein blocks t...
... COLUMBUS, Ga., Feb. 6 Aflac Incorporated,annou... its holdings of,perpetual debenture securities at...nal information to its web site on each,Upper Tier... and elevated a frequently asked questions (FAQ) d...
...plies tend to run dangerously short this time of y... The holiday season is long gone, and everyone has... still one gift left to give, one that,s desperate...tions. Now that the new year is under way, there,s...
... This Valentine,s Day unpro... sweeteners and berries to produce a new type of c...rties. Dieting and the benefits of berry antioxida...ng been regarded as a sweet and sinful indulgence....
...utations could increase cancer risk almost 6-fold,...thDay News) -- Scientists have identified two gene...creased risk of developing thyroid cancer. , This ...cording to the U.S. National Cancer Institute. , "...
... KePRO,s Chief Medical Offi... care and quality of life , ...ce Stollenwerk Petrulis , MD, FACP, has been appoi...and care management, will work with other leading ...
Other Medicine News:Health News:Gene Therapy May Ease Rheumatoid Arthritis 2Health News:Aflac Incorporated Provides Added Detail on Perpetual Debenture Holdings 2Health News:Needed: Blood Donations 2Health News:Needed: Blood Donations 3Health News:Losing Weight with Chocolate on Valentine's Day 2Health News:Gene Test Could Predict Thyroid Cancer Risk 2Health News:Gene Test Could Predict Thyroid Cancer Risk 3Health News:Alice Stollenwerk Petrulis, MD, FACP, Appointed to NQF Care Coordination Committee 2
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
(Date:12/4/2009)HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers of the AcceleDent System , which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Stay Upbeat Active to Keep the Mind Young 49889 1Stay Upbeat Active to Keep the Mind Young 49889 2Stay Upbeat Active to Keep the Mind Young 49889 3WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 1WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 2WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 3WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 410th CyberKnife System Installed at an HCA Hospital 49885 110th CyberKnife System Installed at an HCA Hospital 49885 210th CyberKnife System Installed at an HCA Hospital 49885 310th CyberKnife System Installed at an HCA Hospital 49885 4
...rst study evaluating DUROS(R) continuous delivery ..., , HAYWARD, Calif., April 24 Intarcia Therapeut...t accrual to a phase 1b clinical study evaluating ...e). The study is being conducted at multiple cente... of 44 patients with type 2 diabetes for a period ...
...votal Trial Expected to Initiate in 2010 for Blina...asdaq: MITI ), a biopharmaceutical company devel...ent of cancer, inflammation and autoimmune disease...ancial analysts at The Yale Club of New York City....areas of development across Micromet,s BiTE antibo...
Other Medicine Technology:Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
Serdarevic Suture Hook
Osher "Y" Hook
Fenzl Insertion Hook
Heath Chalazion Curette
Medicine Products: